February 2016

Letter from the Editor

February 1, 2016

Celebrating 15 Years PharmaVOICE has embarked upon a year of celebrating 15 years of raising the voices of tens=of thousands of industry leaders who have provided their time and energy to bringing forward their insights on the trends, challenges, and opportunities impacting an ever-evolving industry. This month we are featuring a special forum — Reflections […]

UpFront

February 1, 2016

Industry at Large Astellas Partners with Aspiritech to Advance Opportunities for Adults with Autism By harnessing the strengths of adults with high-functioning autism — attention to detail, precision, an affinity for repetitive tasks, and outstanding technology skills — Aspiritech is providing software testing and other quality assurance services to Astellas in a wide range of […]

Innovator’s Corner

February 1, 2016

Researching Gene Therapies for Rare Diseases Karen Aiach, Founder and CEO of Lysogene, talks about the company’s mission to become experts in gene vector delivery to the brain. Diseases of the central nervous system are a challenge to treat because the blood brain barrier prevents large molecules such as lysosomal enzymes from entering the brain […]

mHealth

February 1, 2016

Novartis and Qualcomm’s Inhaler Device Helps Manage COPD Trendwatch: Apps and devices create better patient connectivity. Novartis and Qualcomm have collaborated to create the Breezhaler inhaler device to treat COPD. Under this partnership, Qualcomm Life will provide the technology solution for the connectivity of the next generation of the Breezhaler inhaler. Patients will have access […]

Pharma Trax

February 1, 2016

Biopharma Sales Operations Stabilizing Trending now: Growth in sales operations spending driven by changing biopharma challenges and priorities. The biopharmaceutical sales operations rollercoaster ride appears to have leveled off, according to TGaS Advisors. A recent TGaS Commercial Operations Landscape Study shows that operations teams’ efforts to absorb change and new capabilities while reducing levels of […]

What’s New

February 1, 2016

Baxalta Opens Global Innovation Center Trending now:  Baxalta joins growing list of Cambridge, Mass.-based innovators Baxalta, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, has opened its Global Innovation Center in Cambridge, Mass. The center, located in Kendall Square, acts as the innovation hub of the […]

Tools of the Trade

February 1, 2016

Veeva Systems and UL EduNeering Partner to Deliver Integrated Learning Solution Trending Now:  The partnership marries industry cloud solutions to improve quality and compliance across the value chain. UL EduNeering is delivering a connector integrating Veeva Vault QualityDocs, a cloud-based life-sciences document management and control solution, with its ComplianceWire, a learning management system. Developed by […]

The Calendar

February 1, 2016

Coming Attractions The Pennsylvania BIO 2016 Annual Dinner and Awards Celebration is the premier event of the season for the life-sciences industry in Pennsylvania. On March 10th, more than 1,000 attendees will convene for this can’t-miss event Thursday, March 10, 2016, at the PA Convention Center Annex, Terrace Ballroom, in Philadelphia. Numerous awards will be […]

Talent Pool

February 1, 2016

Pharma pool Paris Panayiotopoulos Ariad Names President and CEO Paris Panayiotopoulos has been appointed president and CEO of Ariad, an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. Most recently, Mr. Panayiotopoulos was president of EMD Serono. He succeeds Harvey J. Berger, M.D., Ariad’s founder, chairman, and CEO. […]

Last Word

February 1, 2016

Patient Advocacy in Rare Diseases Michelle Berg, VP of Patient Advocacy at Abeona Therapeutics, talks about the role biopharma companies can play in being a liaison between the scientific community and patients. PV: Why is patient advocacy important in rare diseases? Berg: The role for pharmaceutical companies is to maintain strong relationships and provide solid, […]

Reflections and Predictions

February 1, 2016

The world today is much different from when PharmaVOICE began publishing 15 years ago. In the United States, George W. Bush had just taken office, replacing Bill Clinton. Today, Jeb Bush and Hillary Clinton are running for president. Okay, so while some of the names in politics remain the same, the country and the world […]

Global Launches

February 1, 2016

Most of today’s new therapy launches are global, but the strategy behind those launches has changed significantly, due to the advent of more specialty drugs targeting smaller populations, and the impact of the shift in decision making from physician to payer. The industry can no longer rely on physician promotion only for a successful global […]

Advertising to Segments of the Customer Base

February 1, 2016

For many marketers today, audience segmentation is becoming a key strategic activity when conducting audience analysis. At the most basic level, audience segmentation is the process of dividing a large group of people into homogeneous subgroups — or segments — based upon those who have similar needs or on defined criterion such as product usage, […]

The Coming Antibiotic Crisis

February 1, 2016

For the last 70 years, antibiotics have greatly reduced illness and death from infectious diseases. But these drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. In the past 25 years, there has been a […]

Patients and Patient Organizations Power Rare Disease Therapies

February 1, 2016

For most of the pharmaceutical industry, the focus on patient centricity is a relatively new phenomenon, and the industry continues to shift its focus to include patients as stakeholders when planning its marketing strategies, clinical trials, and R&D strategies. However, for the rare disease sector, the patient has always been front and center, championing for […]

Mental Illness: An Underserved Area

February 1, 2016

Advances in brain science and the understanding of mental health disorders have led to the approval of new medicines, but mental health disorders still take a huge toll on Americans. The National Institute of Mental Health (NIMH) estimates that one in four American adults — 61.5 million people — have been diagnosed with a mental […]

Alzheimer’s Research Update

February 1, 2016

Alzheimer’s is at the forefront of brain research; 90% of what we know about Alzheimer’s has been discovered in the last 15 years. But while research has discovered much about this devastating disease, there is still much we don’t know. Alzheimer’s is one of the most complex diseases researchers have ever studied. There are many […]

Quiet Achiever: Japan Puts Focus On Innovation

February 1, 2016

A s one of the world’s biggest economies and a well-established pharmaceutical powerhouse, Japan has for many years been a difficult market for foreign companies to enter independently. Increasingly, however, the Japanese market is opening to international companies. “In the past companies were essentially entering the market through joint ventures with local Japanese pharmaceutical companies; now […]

SHOWCASE FEATURE: Outsourcing: Strategic Partnerships

February 1, 2016

After years of paying lip service to the need for truly strategic partnerships between sponsors and CROs as a way to increase efficiencies, improve timelines to market, and reduce costs, the time may be right for both parties. According to Nice Insights’ most recent survey 2016 CRO Buying Trends, 77% of respondents reported that it […]

Countdown to Launch: Strategies For Efficiency, Acceleration and Performance

February 1, 2016

As new drug launches proliferate in the increasingly complex specialty therapeutic space, biopharma is finding that success is often pre-determined by actions that take place very early in the development and commercialization cycle. In fact, the earlier companies start thinking through their launch strategy, the better. In particular, emerging companies that are pouring in millions […]

FEEDBACK